Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
|Articles|March 22, 2005
Pharmaceutical Technology Europe
- Pharmaceutical Technology Europe-03-01-2005
- Volume 17
- Issue 3
The Application of Cryogenics for Sustainable Solvent Recovery
Author(s)Jon Trembley
Emissions control has long been a primary concern for the pharmaceutical processing industry in Europe, which relies on the use of a number of organic solvents for the manufacture of pharmaceutical products...
Advertisement
Articles in this issue
over 21 years ago
Taming the Regulatory Beast: Regulation versus Functionalismover 21 years ago
Field-Flow Fractionation With Multiangle Light Scatteringover 21 years ago
Big Pharma Smells Parallel Trade Victoryover 21 years ago
Keeping Supply Chains Healthyover 21 years ago
Current Trends in Biomanufacturingover 21 years ago
The European Search for Researchover 21 years ago
European Biotech Second to USAdvertisement
Related to this article
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Jason Bertola, executive director of Commercial Development for the Advanced Synthesis Platform at Lonza in North America, explains the demand for spray drying and the hurdles involved with scale up, in an interview with PharmTech.
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
2
What the Olanzapine Depot Approval Means for CMC Teams
3
Complying with International Pharmacopoeias
4
PharmTech AI Pulse Check: Availability Bias Threatens AI Regulatory Reviews
5